Highly selective and sensitive potentiometric determination of favipiravir in COVID-19 antiviral drug formulations

被引:1
|
作者
Topcu, Cihan [1 ]
Aydin, Senanur [1 ]
Atasoy, Betul Hilal [1 ]
Yilmaz, Rabia Rana [1 ]
Coldur, Fatih [2 ]
Caglar, Bulent [3 ]
机构
[1] Samsun Univ, Fac Engn & Nat Sci, Dept Biomed Engn, Samsun, Turkiye
[2] Erzincan Binali Yildirim Univ, Fac Arts & Sci, Dept Chem, Erzincan, Turkiye
[3] Ondokuz Mayis Univ, Dept Food Feed & Med, Inst Hemp Res, Samsun, Turkiye
关键词
COVID-19; Favipiravir; Electrochemical favipiravir sensor; Potentiometry; ELECTRODE; CONSTRUCTION; COPPER(II); SENSOR; IONS;
D O I
10.1016/j.microc.2024.111390
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
In this study, a novel all-solid-state electrochemical sensor based on favipiravir-tetraphenylborate (FAV-TPB) electroactive material was developed and reported for FAV's highly selective and sensitive potentiometric determination in COVID-19 antiviral drug formulations. All-solid-state FAV selective sensor was fabricated by mixing and properly pressing FAV-TPB, graphite (G), multi-walled carbon nanotube (MWCNT), and paraffin oil (PO). In order to obtain the best sensor response, the sensor component ratios were optimized. The most satisfying response characteristics was obtained with the sensor composition FAV-TPB:G:MWCNT:PO in the ratio 32.5:42.5:5:20 (w/w %). The developed sensor displayed a wide linear near-Nernstian response to FAV over the concentration of 1.0 x 10-6 - 1.0 x 10- 1 molL- 1 with a slope of 53.6 +/- 1.4 mV (R2 = 0.9997). The detection limits of the sensor was calculated as 6.0 x 10- 7molL- 1, respectively. The dynamic response time of the sensor was 7 s, and the sensor exhibited fairly reproducible potentiometric responses. In the pH range of 6.0-8.0, the sensor's potential response was not affected by the pH change of the test solutions. The improved sensor had a wide temperature tolerance, and its response remained unchanged in the 10-40 degree celsius temperature range. The interference effect of some chemical and biological species was evaluated by the matched potential method and separate solution method. The sensor worked stable for 12 weeks without any considerable change in its potential response. The analytical applications of the sensor were successfully carried out with the potentiometric titration of FAV with sodium tetraphenylborate solution and also the direct determination of favipiravir in COVID-19 antiviral drug formulations.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Favipiravir, an antiviral for COVID-19?
    Coomes, Eric A.
    Haghbayan, Hourmazd
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (07) : 2013 - 2014
  • [2] Comment on: Favipiravir, an antiviral for COVID-19?
    Chachaima-Mar, Jorge
    Perez-Castilla, Jesus
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (01) : 279 - 280
  • [3] Voltammetric Determination of Favipiravir Used as an Antiviral Drug for the Treatment of Covid-19 at Pencil Graphite Electrode
    Ersan, Teslime
    Dilgin, Didem Giray
    Kumrulu, Elif
    Kumrulu, Umur
    Dilgin, Yusuf
    ELECTROANALYSIS, 2023, 35 (04)
  • [4] Development and Validation of HPLC-DAD Method for the Determination of Favipiravir and Studying the Impact of Vitamin C on the Pharmacokinetics of COVID-19 Antiviral Drug Favipiravir
    Hailat, Mohammad
    Al-Ani, Israa
    Zakareia, Zainab
    Al-Shdefat, Ramadan
    Al-Meanazel, Osaid
    Anwer, Md Khalid
    Hamad, Mohammed
    Abu Rayyan, Walid
    Awad, Riad
    Abu Dayyih, Wael
    SEPARATIONS, 2022, 9 (10)
  • [5] An antiviral drug for covid-19?
    Benestad, Haakon B.
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2021, 141 (12) : 1176 - 1176
  • [6] Potentiometric Determination of Betahistine in Pharmaceutical Formulations by Drug Selective Sensors
    Ganjali, Mohammad Reza
    Aghili, Sarah
    Larijani, Bagher
    Ghasemi, Mohammad Hadi
    INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE, 2015, 10 (02): : 1893 - 1903
  • [7] Novel Formulations of the Antiviral Drug Favipiravir: Improving Permeability and Tabletability
    Wang, Xinyuan
    Wang, Lei
    Yao, Changlin
    Xie, Guanying
    Song, Shuhong
    Li, Huimin
    Qu, Yaqian
    Tao, Xutang
    CRYSTAL GROWTH & DESIGN, 2021, 21 (07) : 3807 - 3817
  • [8] Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences
    Shiraki, Kimiyasu
    Sato, Noriaki
    Sakai, Kaoru
    Matsumoto, Shirou
    Kaszynski, Richard H.
    Takemoto, Masaya
    PHARMACOLOGY & THERAPEUTICS, 2022, 235
  • [9] Favipiravir for treating COVID-19
    Korula, Pritish
    Alexander, Hanna
    John, Jisha Sara
    Kirubakaran, Richard
    Singh, Bhagteshwar
    Tharyan, Prathap
    Rupali, Priscilla
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2024, (02):
  • [10] Alectinib, COVID-19 and favipiravir
    Mungmunpuntipantip, Rujittika
    Wiwanitkit, Viroj
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (07) : 1810 - 1810